View in EDS PDF Full Text

Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.

Saved in:
Bibliographic Details
Title: Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.
Authors: Williams, R., Kopala, L., Malla, A., Smith, G., Love, L., Balshaw, R.
Source: Acta Psychiatrica Scandinavica. Supplementum. May2006 Supplement 430, Vol. 113, p12-21. 10p. 1 Diagram, 12 Charts, 1 Graph.
Subjects: Health outcome assessment, Schizophrenia, Clozapine, Risperidone, Olanzapine, Antipsychotic agents
Geographic Terms: Canada
Abstract: Objective: To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment. Method: A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years. Results: Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized. Conclusion: There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period. [ABSTRACT FROM AUTHOR]
Copyright of Acta Psychiatrica Scandinavica. Supplementum is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 20069276
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Williams%2C+R%2E%22">Williams, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Kopala%2C+L%2E%22">Kopala, L.</searchLink><br /><searchLink fieldCode="AR" term="%22Malla%2C+A%2E%22">Malla, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Smith%2C+G%2E%22">Smith, G.</searchLink><br /><searchLink fieldCode="AR" term="%22Love%2C+L%2E%22">Love, L.</searchLink><br /><searchLink fieldCode="AR" term="%22Balshaw%2C+R%2E%22">Balshaw, R.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Acta+Psychiatrica+Scandinavica%2E+Supplementum%22">Acta Psychiatrica Scandinavica. Supplementum</searchLink>. May2006 Supplement 430, Vol. 113, p12-21. 10p. 1 Diagram, 12 Charts, 1 Graph.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Health+outcome+assessment%22">Health outcome assessment</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia%22">Schizophrenia</searchLink><br /><searchLink fieldCode="DE" term="%22Clozapine%22">Clozapine</searchLink><br /><searchLink fieldCode="DE" term="%22Risperidone%22">Risperidone</searchLink><br /><searchLink fieldCode="DE" term="%22Olanzapine%22">Olanzapine</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Canada%22">Canada</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment. Method: A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years. Results: Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized. Conclusion: There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Acta Psychiatrica Scandinavica. Supplementum is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=20069276
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/j.1600-0447.2006.00757.x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 12
    Subjects:
      – SubjectFull: Health outcome assessment
        Type: general
      – SubjectFull: Schizophrenia
        Type: general
      – SubjectFull: Clozapine
        Type: general
      – SubjectFull: Risperidone
        Type: general
      – SubjectFull: Olanzapine
        Type: general
      – SubjectFull: Antipsychotic agents
        Type: general
      – SubjectFull: Canada
        Type: general
    Titles:
      – TitleFull: Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Williams, R.
      – PersonEntity:
          Name:
            NameFull: Kopala, L.
      – PersonEntity:
          Name:
            NameFull: Malla, A.
      – PersonEntity:
          Name:
            NameFull: Smith, G.
      – PersonEntity:
          Name:
            NameFull: Love, L.
      – PersonEntity:
          Name:
            NameFull: Balshaw, R.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 05
              Text: May2006 Supplement 430
              Type: published
              Y: 2006
          Identifiers:
            – Type: issn-print
              Value: 00651591
          Numbering:
            – Type: volume
              Value: 113
          Titles:
            – TitleFull: Acta Psychiatrica Scandinavica. Supplementum
              Type: main
ResultId 1